Education
About Us
Working with TipRanks
Follow Us
Defence Therapeutics (DTCFF)
OTHER OTC:DTCFF
DTCFF Stock Chart & Stats
$0.58
$0.06(15.36%)
At close: 4:00 PM EST
$0.58
$0.06(15.36%)
Day’s Range― - ―
52-Week Range$0.31 - $1.00
Previous CloseN/A
Volume8.00K
Average Volume (3M)599.00
Market Cap
$25.60M
Enterprise Value$33.92M
Total Cash (Recent Filing)$947.35K
Total Debt (Recent Filing)$1.49M
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding57,369,970
10 Day Avg. Volume40
30 Day Avg. Volume599
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market Cap1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-758.48
Enterprise Value/Ebitda-8.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Accum™ Delivery PlatformA proprietary intracellular delivery platform is a durable competitive asset: it can be applied across ADCs, vaccines and biologics, enabling differentiated payload delivery and immune enhancement. This technical moat supports long-term pipeline optionality and potential partner licensing opportunities.
Focus On Oncology And Infectious DiseaseConcentrating R&D on oncology and infectious disease aligns the company with structural, high-demand markets where improved delivery and immune activation are prioritized. This sector focus increases long-term commercial potential and relevance of the Accum™ platform across large addressable markets.
Improving Reported Losses And FCF TrendA material reduction in annual losses and an improvement in free cash flow growth are constructive operating signals. If sustained, these trends point to improved cost discipline and better cash runway dynamics, lowering near-term financing needs and supporting longer-term R&D continuity.
Bears Say
Zero Revenue BaseThe company reports no revenue and negative gross profit, indicating no commercialization to fund operations. This structural lack of product revenue means continued dependence on capital markets or partnerships to finance R&D, raising execution and dilution risk over the medium term.
Negative Shareholders' EquityNegative shareholders' equity signals accumulated losses and dilution that reduce financial flexibility. This structural weakness complicates leverage interpretation, increases refinancing or dilution risk, and can hinder strategic transactions or partner confidence over the coming months.
Sustained Negative Operating Cash FlowPersistent negative operating cash flow (~-4.9M TTM) demonstrates ongoing cash burn and reliance on external funding. Structurally, this constrains near-term investment capacity, increases financing needs, and elevates execution risk if capital access tightens or costs rise.
Defence Therapeutics News
DTCFF FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was $0.31 and its highest was $1.00 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is $25.60M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is May 22, 2026 which is in 79 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on Feb 20, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.02.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 57,369,970 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -$0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DTCFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―